• CloudMD (DOC) to participate in upcoming Laurentian Bank and Bloom Burton & Co. investor conferences
  • The Laurentian Bank Securities Annual Institutional Investor Conference will take place from April 6 to 9, 2021
  • Bloom Burton & Co. Annual Healthcare Investor Conference will take place from April 20 to 21, 2021
  • CloudMD is digitizing the delivery of healthcare by providing a patient-centric approach
  • CloudMD Software & Services Inc. (DOC) is up 1.86 per cent and is trading at C$1.92 at 3:02 pm ET

CloudMD Software & Services Inc. (DOC) has been invited to participate in the upcoming Laurentian Bank Securities and Bloom Burton & Co. investor conferences.

The Laurentian Bank Securities Annual Institutional Investor Conference will take place from April 6 to 9, 2021.

On Thursday, April 8, 2021, at 12:45 pm ET, Diversified Technology Track’s topic will be discussed.

Dr. Essam Hamza will participate in a panel discussion titled, Digital Healthcare: Where To From Here?

Members of management will also be participating in one-on-one investor meetings.

Investors should contact a Laurentian Bank Securities representative for more information and to schedule one-on-one meetings with management.

The Bloom Burton & Co. Annual Healthcare Investor Conference will take place from April 20 to 21, 2021.

Dr. Essam Hamza will be presenting CloudMD and providing an update on the business via a webinar. Members of management will also be participating in one-on-one investor meetings during the conference.

CloudMD is digitizing healthcare delivery by providing a patient-centric approach, with an emphasis on continuity of care.

By leveraging healthcare technology, CloudMD is building one connected platform that addresses all points of a patient’s healthcare journey and provides better access to care and improved outcomes. 

CloudMD Software & Services Inc. (DOC) is up 1.86 per cent and is trading at C$1.92 at 3:02 pm ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.